Indicators on LY 3000328 You Should Know
All enrolled sufferers who been given at least one particular dose of zosuquidar or placebo throughout induction were being monitored for the event of adverse activities (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse events had been relevant to the duration of prolonged and important myelosuppression as is predicted with